Adaptimmune Therapeutics Ownership | Who Owns Adaptimmune Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Adaptimmune Therapeutics Ownership Summary

Adaptimmune Therapeutics is owned by 8.10% institutional investors, 0.32% insiders, and 91.58% retail investors. Bank of america corp /de/ is the largest institutional shareholder, holding 1.92% of ADAP shares. Edinburgh Worldwide Ord is the top mutual fund, with 2.05% of its assets in Adaptimmune Therapeutics shares.

ADAP Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Adaptimmune Therapeutics	8.10%	0.32%	91.58%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Bank of america corp /de/	4.65M	1.92%	$4.53M
Ecor1 capital	27.40M	1.79%	$14.76M
Long focus capital management	20.49M	1.34%	$11.04M
Nea management company	17.08M	1.11%	$9.20M
Two seas capital lp	14.84M	0.97%	$7.99M
Baillie gifford	11.82M	0.77%	$6.37M
Mpm asset management	5.56M	0.36%	$2.99M
Bioimpact capital	5.10M	0.33%	$2.75M
Pfm health sciences, lp	4.87M	0.32%	$2.62M
Morgan stanley	440.83K	0.18%	$429.77K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Mpm asset management	5.56M	2.41%	$2.99M
Two seas capital lp	14.84M	0.69%	$7.99M
Ecor1 capital	27.40M	0.56%	$14.76M
Nea management company	17.08M	0.52%	$9.20M
Bioimpact capital	5.10M	0.39%	$2.75M
Long focus capital management	20.49M	0.36%	$11.04M
Pfm health sciences, lp	4.87M	0.16%	$2.62M
Key client fiduciary advisors	255.36K	0.06%	$137.56K
Rock springs capital management lp	2.48M	0.05%	$1.34M
Redmile group	715.61K	0.03%	$385.50K

Top Buyers

Holder	Shares	% Assets	Change
Two seas capital lp	14.84M	0.69%	14.84M
Long focus capital management	20.49M	0.36%	7.19M
Renaissance	2.53M	0.00%	869.95K
Acadian asset management	510.22K	0.00%	510.22K
Jane street group	326.94K	-	152.78K

Top Sellers

Holder	Shares	% Assets	Change
Matrix capital management company, lp	-	-	-37.68M
Pfm health sciences, lp	4.87M	0.16%	-5.13M
Baillie gifford	11.82M	0.00%	-4.96M
Baker bros. advisors lp	-	-	-2.34M
Tang capital management	-	-	-1.74M

New Positions

Holder	Shares	% Assets	Change	Value
Two seas capital lp	14.84M	0.69%	14.84M	$7.99M
Acadian asset management	510.22K	0.00%	510.22K	$269.00K
Hrt financial lp	83.20K	0.00%	83.20K	$44.00K
Raymond james financial	31.08K	-	31.08K	$16.74K
Kingswood wealth advisors	18.69K	0.00%	18.69K	$10.07K

Sold Out

Holder	Change
National bank of canada /fi/	-10.00
Northwestern mutual wealth management	-69.00
Royal bank of canada	-700.00
Wetzel investment advisors	-6.00K
Signaturefd	-6.62K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2024	79	-2.47%	124,313,247	-18.02%	8	8.30%	30	-18.92%	21	40.00%
Sep 30, 2024	79	-1.25%	151,643,820	-1.46%	59	1.46%	36	56.52%	15	-31.82%
Jun 30, 2024	80	-3.61%	153,896,694	-5.05%	63	1.25%	23	-32.35%	22	-
Mar 31, 2024	83	9.21%	162,089,971	12.87%	71	0.64%	34	21.43%	22	-12.00%
Dec 31, 2023	76	-1.30%	143,609,879	-3.14%	105	1.64%	28	21.74%	25	4.17%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Edinburgh Worldwide Ord	5.28M	2.05%	-
Baillie Gifford Global Discovery A Acc	3.31M	1.29%	15.10K
Baillie Gifford WW Discovery B USD Acc	1.59M	0.62%	55.00
JPM Thematics Genetic Thrps C2 Acc USD	913.17K	0.36%	-26.08K
JPM Thematics Genetic Thrps C2 dist USD	881.69K	0.34%	-
Galileo - Biotech Innovation Fund S USD	752.46K	0.29%	-
Mercer Global Small Cap Equity M-5£	635.81K	0.25%	-
Mercer Global Small Cap Equity M-3£	484.78K	0.19%	84.40K
SPDR® Portfolio Developed Wld ex-US ETF	276.75K	0.11%	-
SEI International Equity F (SIT)	246.74K	0.10%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jan 17, 2025	Norry Elliot	Chief Medical Officer	Sell	$3.24K
Jan 17, 2025	Lunger John	Chief Patient Supply Officer	Sell	$3.24K
Jan 17, 2025	Bertrand William C JR	Chief Operating Officer	Sell	$3.24K
Jan 17, 2025	Rawcliffe Adrian	Chief Executive Officer	Sell	$17.77K
Jan 13, 2025	Rawcliffe Adrian	Chief Executive Officer	Sell	$7.37K

Insider Transactions Trends

Date	Buy	Sell
2025 Q1	-	17
2024 Q3	-	-
2024 Q2	-	1
2024 Q1	-	19
2023 Q4	-	-

ADAP Ownership FAQ

Who Owns Adaptimmune Therapeutics?

Adaptimmune Therapeutics shareholders are primarily institutional investors at 8.10%, followed by 0.32% insiders and 91.58% retail investors. The average institutional ownership in Adaptimmune Therapeutics's industry, Biotech Stocks , is 68.48%, which Adaptimmune Therapeutics falls below.

Who owns the most shares of Adaptimmune Therapeutics?

Adaptimmune Therapeutics’s largest shareholders are Bank of america corp /de/ (4.65M shares, 1.92%), Ecor1 capital (27.4M shares, 1.79%), and Long focus capital management (20.49M shares, 1.34%). Together, they hold 5.05% of Adaptimmune Therapeutics’s total shares outstanding.

Does Blackrock own Adaptimmune Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Adaptimmune Therapeutics.

Who is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.41% of its assets in 5.56M Adaptimmune Therapeutics shares, valued at 2.99M$.

Who is the top mutual fund holder of Adaptimmune Therapeutics shares?

Edinburgh Worldwide Ord is the top mutual fund holder of Adaptimmune Therapeutics shares, with 2.05% of its total shares outstanding invested in 5.28M Adaptimmune Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools